Healthy volunteers help uncover drug interaction secrets
NCT ID NCT07439250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 1 study looked at how the antifungal drug fluconazole changes the way the body handles the experimental cancer drug olomorasib. Fifteen healthy volunteers took olomorasib alone and then with fluconazole, and researchers measured drug levels in their blood. The goal was to understand if fluconazole affects how much olomorasib gets into the bloodstream and how quickly it is eliminated.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- olomorasib (LY3537982) and fluconazole
- What this could lead to
- If successful, this study will help doctors understand how to safely dose olomorasib when taken with fluconazole, potentially improving treatment for future patients.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures drug levels in the blood, not whether the drug works or is safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
15 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Must have a Body Mass Index (BMI) within the range of 18.0 to 30.0 kilograms per square meter (kg/m2) * Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP). Exclusion Criteria: * History or presence of the following conditions: * metabolic disease * biliary disease * gastrointestinal disease * hematological disease * neurological disease * significant history of hepatic disease * clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to Day 1 * Abnormal blood pressure or pulse rate * Have a 12-lead electrocardiogram (ECG) abnormality, in the opinion of the investigator, increases the risks associated with participating in the study, or may confound ECG analysis * History of malignancy within 5 years prior to screening, except for basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the cervix, that have been resected with no evidence of metastatic disease for 3 years. * Show evidence of Human Immunodeficiency Virus (HIV) infection or positive HIV antibodies * Have a positive hepatitis C antibody test * Have evidence of hepatitis B at screening, that is, positive test for hepatitis B surface antigen, Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA), or both. * Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation * Use of tobacco, smoking-cessation products, electronic (e)-cigarettes (nicotine and non-nicotine), or nicotine products within 90 days prior to first olomorasib administration and through the end of trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chewable postbiotic tablet keep plaque and gum inflammation at bay?
- Can a new oral drug safely help older adults manage weight?
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others